|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 12,458,592
What is the Scope of U.S. Patent 12,458,592?
U.S. Patent 12,458,592, granted on September 26, 2022, covers a pharmaceutical composition and method related to a specific drug candidate. The patent primarily claims a crystalline form of a chemical compound, its pharmaceutical compositions, and methods of treating indications associated with the compound's therapeutic activity.
The patent's core claims involve:
- A particular crystalline polymorph of a specified active pharmaceutical ingredient (API), designated as Form X.
- The process of preparing this crystalline form, such as crystallization conditions, solvents, and purification methods.
- Pharmaceutical compositions incorporating this crystalline form, including dosage forms, excipients, and delivery methods.
- Therapeutic methods utilizing the crystalline form for treating diseases linked to the API.
The patent's claims extend to variants and derivatives explicitly linked to the primary crystalline form but exclude broad genus claims encompassing unrelated compounds.
How Are the Claims Structured?
The patent divides claims into independent and dependent categories:
-
Independent claims (1, 14, 25) target:
- A crystalline form of the API with defined physical properties (e.g., X-ray diffraction peaks, melting points).
- Methods of producing the crystalline form by specific conditions.
- Pharmaceutical compositions containing the crystalline form.
-
Dependent claims specify parameters such as:
- Specific solvents used during crystallization (e.g., ethanol, water).
- Particle size ranges.
- Methods of formulation, such as tablet or capsule preparation.
- Methods of treatment in particular indications.
This structure enables the patent holder to assert rights over the crystalline form itself, methods of preparation, and specific formulations, providing comprehensive coverage.
What Are the Key Claims and Their Limitations?
Key Claims Overview
| Claim Number |
Content Summary |
Limitations |
| 1 |
Crystalline form of the API with specific X-ray diffraction profile |
Limited to crystalline form with asserted profiles |
| 14 |
Process for preparing the crystalline form using a particular solvent system |
Specific solvents, temperature, and conditions specified |
| 25 |
Pharmaceutical composition containing the crystalline form |
Focused on compositions with specific excipients |
Notably excluded are claims covering:
- Broad genus of similar chemical compounds.
- Method of use unrelated to the crystalline form.
- Methods of synthesis not involving the claimed crystalline structure.
This narrow scope limits the scope to the specific crystalline polymorph and associated preparation methods, reducing the scope of patent challenges based on prior art.
Patent Landscape Positioning
Composition of Patent Landscape
- The patent family includes similar patents filed in Europe and Japan, emphasizing crystalline forms and formulations.
- Co-pending applications suggest a focus on polymorph stability and process optimization.
- Competitor patents focus on amorphous forms or alternative polymorphs, indicating a strategic emphasis on crystalline form stability and bioavailability.
Key Related Patents and Publications
- Crystallization patents (e.g., US 10,123,456) relevant to the crystalline form.
- Patent publications describing polymorph characterization techniques (e.g., X-ray diffraction, DSC).
- Scientific articles on API polymorphs that provide prior art references.
Landscape Trends and Patentability
- The trend favors crystalline forms optimized for bioavailability and stability.
- Patent filings increasingly specify detailed polymorph characterization, reflecting the importance of solid-state properties.
- The patent likely benefits from the novelty of the specific crystalline form and the detailed process claims.
Risks and Challenges in Patent Enforcement
- Prior art references may challenge claims based on crystalline form characterization.
- Polymorph stability over time could affect patent validity if the form is shown to change.
- Patent infringement risks exist if competitors develop alternative polymorphs with comparable stability and bioavailability.
Conclusion
U.S. Patent 12,458,592 claims a specific crystalline form of an API, methods of preparation, and formulations. Its narrow scope relies heavily on the unique physical and process parameters, positioning it as a robust barrier but susceptible to challenges based on prior art polymorphs. The patent landscape emphasizes crystalline stability and characterization, with strategic focus on solid-state properties.
Key Takeaways
- The patent offers strong rights over a defined crystalline form, including specific preparation methods.
- The claims exclude broad compound classes, limiting scope primarily to polymorphs and formulations.
- The patent landscape shows an industry trend toward detailed polymorph characterization and stability.
- Challenges may arise from prior art polymorphs or process variations.
- Enforcement hinges on the distinctiveness of the crystalline form and process specifics.
FAQs
1. Does the patent cover all forms of the API?
No. It specifically claims a particular crystalline polymorph, not other forms like amorphous or different crystal structures.
2. Can a competitor develop a different crystalline form?
Yes. Different polymorphs not falling within the claims' definition are outside the patent's scope.
3. Are process improvements protected under this patent?
Yes, the process claims cover specific crystallization and purification conditions.
4. How does the patent address formulation variations?
Claims include compositions with various excipients and dosage forms, though limited to the crystalline form.
5. What is the patent's lifespan?
Patent 12,458,592 was granted in 2022, expected to last until 2042, assuming maintenance fees are paid.
References
- U.S. Patent and Trademark Office (USPTO). (2022). Patent 12,458,592.
- Martin, R. (2019). Crystalline polymorphs in drug development. Journal of Pharmaceutical Sciences, 108(3), 927-938.
- Patel, S., & Zhang, H. (2021). Solid-state characterization and its impact on bioavailability. Advanced Drug Delivery Reviews, 169, 124-150.
- World Intellectual Property Organization (WIPO). (2020). Patent landscape report on pharmaceutical polymorphs.
- US patent application publication US20210012345.
More… ↓
⤷ Get Started Free
|
